You are here: Industry Insights > Polyganics

News List

Polyganics Achieves CE Mark Certification for LIQOSEAL® b3cnewswire
January 16, 2020
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has obtained CE marking for LIQOSEAL®, its easy-to-use and innovative dural sealant patch ...
Polyganics Achieves Positive 3-month Follow-up Data of ENCASE I, the First Clinical Trial for LIQOSEAL® b3cnewswire
September 18, 2019
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, has today announced positive data from its ENCASE I* clinical trial.
Polyganics Initiates First-in-Human Trial of LIQOSEAL®, its Innovative Approach for Dural Closure b3cnewswire
November 10, 2018
The trial, titled ‘ENCASE’, is a single-arm, open-label study, evaluating safety and performance of LIQOSEAL® in reducing CSF leakage following elective cranial surgery. Up to 40 adult patients will be recruited at three sites across the Netherlands and S
FDA Grants Breakthrough Device Designation to Polyganics’ Liver and Pancreas Sealant Patch biospace
March 09, 2018
Polyganics, today announced that the US Food and Drug Administration (FDA) has granted Polyganics’ request for Breakthrough Device designation to its Liver and Pancreas Sealant Patch.
Polyganics Awarded €1.2 Million to Complete Clinical Development of Dura Sealant Patch b3cnewswire
December 04, 2017
Polyganics today announced that it has received funding from the European Development Fund for the Community for its clinical validation of the European Union's patch of dura mater sealant. Allocations and donations from Groningen and the province totaled